The common pathobiology between coronary artery disease and calcific aortic stenosis: Evidence and clinical implications.

[1]  M. Emmert,et al.  Have we found the missing link between inflammation, fibrosis, and calcification in calcific aortic valve disease? , 2023, European heart journal.

[2]  Joshua D. Hutcheson,et al.  Sortilin enhances fibrosis and calcification in aortic valve disease by inducing interstitial cell heterogeneity , 2023, European heart journal.

[3]  D. Bandyopadhyay,et al.  Lipid Lowering Therapy: An Era Beyond Statins. , 2022, Current problems in cardiology.

[4]  W. Rosamond,et al.  Life’s Essential 8: Updating and Enhancing the American Heart Association’s Construct of Cardiovascular Health: A Presidential Advisory From the American Heart Association , 2022, Circulation.

[5]  E. Țarcă,et al.  Etiologic Puzzle of Coronary Artery Disease: How Important Is Genetic Component? , 2022, Life.

[6]  Prashanth Rawla,et al.  Valvular Heart Disease Epidemiology , 2022, Medical sciences.

[7]  M. Clark,et al.  Mental Stress and Its Effects on Vascular Health , 2022, Mayo Clinic Proceedings.

[8]  D. Bark,et al.  Calcific Aortic Stenosis—A Review on Acquired Mechanisms of the Disease and Treatments , 2021, Frontiers in Cardiovascular Medicine.

[9]  B. Prendergast,et al.  2021 ESC/EACTS Guidelines for the management of valvular heart disease. , 2021, European heart journal.

[10]  Jeroen J. Bax,et al.  Association between Aortic Valve Calcification Progression and Coronary Atherosclerotic Plaque Volume Progression in the PARADIGM Registry. , 2021, Radiology.

[11]  M. Nyegaard,et al.  Sortilin as a Biomarker for Cardiovascular Disease Revisited , 2021, Frontiers in Cardiovascular Medicine.

[12]  P. Libby.  The changing landscape of atherosclerosis , 2021, Nature.

[13]  E. Barbato,et al.  Pathophysiology, Diagnosis, and Treatment of Patients with Concomitant Severe Aortic Stenosis and Coronary Artery Disease: A Closer Look to the Unresolved Perplexity , 2021, Journal of clinical medicine.

[14]  D. Berman,et al.  Prognostic significance of aortic valve calcium in relation to coronary artery calcification for long-term, cause-specific mortality: results from the CAC Consortium. , 2020, European heart journal cardiovascular Imaging.

[15]  M. Rattazzi,et al.  Current Evidence and Future Perspectives on Pharmacological Treatment of Calcific Aortic Valve Stenosis , 2020, International journal of molecular sciences.

[16]  O. Alfieri,et al.  Severe aortic stenosis in the young, with or without bicuspid valve: is transcatheter aortic valve implantation the first choice? , 2020, European heart journal supplements : journal of the European Society of Cardiology.

[17]  K. Nasir,et al.  Lipoprotein(a) levels and association with myocardial infarction and stroke in a nationally representative cross-sectional US cohort. , 2020, Journal of clinical lipidology.

[18]  J. Leopold.  PCSK9 and Calcific Aortic Valve Stenosis , 2020, JACC. Basic to translational science.

[19]  F. Rodriguez,et al.  Lipoprotein(a) and Cardiovascular Disease Prevention across Diverse Populations , 2020, Cardiology and Therapy.

[20]  U. Landmesser,et al.  Calcific Aortic Valve Disease-Natural History and Future Therapeutic Strategies , 2020, Frontiers in Pharmacology.

[21]  K. Koh,et al.  Lipoprotein(a) and Cardiovascular Diseases　- Revisited. , 2020, Circulation journal : official journal of the Japanese Circulation Society.

[22]  M. Budoff,et al.  Effect of statins on atherosclerotic plaque. , 2019, Trends in cardiovascular medicine.

[23]  Supriyo Chakraborty,et al.  A review on coronary artery disease, its risk factors, and therapeutics , 2019, Journal of cellular physiology.

[24]  M. Yacoub,et al.  Rheumatic aortic valve disease-when and who to repair? , 2019, Annals of cardiothoracic surgery.

[25]  Odyssey Outcomes Investigators.  Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome , 2018 .

[26]  K. Koh,et al.  Inflammatory and metabolic mechanisms underlying the calcific aortic valve disease. , 2018, Atherosclerosis.

[27]  Volkmar Falk,et al.  2018 ESC/EACTS Guidelines on myocardial revascularization. , 2018, European heart journal.

[28]  B. Carabello,et al.  Aortic stenosis , 2018, Rapid Cardiac Care.

[29]  P. Jüni,et al.  Five‐Year Outcomes with PCI Guided by Fractional Flow Reserve , 2018, The New England journal of medicine.

[30]  William J. Astle,et al.  Risk thresholds for alcohol consumption: combined analysis of individual-participant data for 599 912 current drinkers in 83 prospective studies , 2018, The Lancet.

[31]  J. Lincoln,et al.  Calcific Aortic Valve Disease: a Developmental Biology Perspective , 2018, Current Cardiology Reports.

[32]  L. Zuo,et al.  Recent Advances in Treatment of Coronary Artery Disease: Role of Science and Technology , 2018, International journal of molecular sciences.

[33]  P. Kolh,et al.  [2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS.] , 2018, Kardiologia polska.

[34]  A. Mammen,et al.  Statins: pros and cons. , 2017, Medicina clinica.

[35]  H. Crijns,et al.  Calcific aortic valve stenosis: hard disease in the heart , 2017, European heart journal.

[36]  Deepak L. Bhatt,et al.  Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease , 2017, The New England journal of medicine.

[37]  Alan D. Lopez,et al.  Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015 , 2017, Journal of the American College of Cardiology.

[38]  R. Hajar.  Risk Factors for Coronary Artery Disease: Historical Perspectives , 2017, Heart views : the official journal of the Gulf Heart Association.

[39]  B. H. van den Born,et al.  Ethnicity, lipids and cardiovascular disease , 2017, Current opinion in lipidology.

[40]  A. Keech,et al.  Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease , 2017, The New England journal of medicine.

[41]  J. Ferrières,et al.  β blockers and mortality after myocardial infarction in patients without heart failure: multicentre prospective cohort study , 2016, British Medical Journal.

[42]  U. Thadani.  Management of Stable Angina – Current Guidelines: A Critical Appraisal , 2016, Cardiovascular Drugs and Therapy.

[43]  C. Otto,et al.  Calcific aortic stenosis , 2016, Nature Reviews Disease Primers.

[44]  G. Garcı́a-Cardeña,et al.  Endothelial Cell Dysfunction and the Pathobiology of Atherosclerosis. , 2016, Circulation research.

[45]  H. Nafakhi,et al.  Aortic Root Calcification: A Possible Imaging Biomarker of Coronary Atherosclerosis , 2016, Pulse.

[46]  Wei Liu,et al.  Current understanding of coronary artery calcification , 2015, Journal of geriatric cardiology : JGC.

[47]  E. Ohman,et al.  Pharmacological and emerging therapies in the treatment of chronic angina , 2015, The Lancet.

[48]  M. Dweck,et al.  Calcification in Aortic Stenosis: The Skeleton Key. , 2015, Journal of the American College of Cardiology.

[49]  I. Savelieva,et al.  Relative efficacy of antianginal drugs used as add-on therapy in patients with stable angina: A systematic review and meta-analysis , 2015, European journal of preventive cardiology.

[50]  N. Peek,et al.  Cardiac rehabilitation and survival in a large representative community cohort of Dutch patients. , 2015, European heart journal.

[51]  M. Sturek,et al.  Benefits of exercise training on coronary blood flow in coronary artery disease patients. , 2015, Progress in cardiovascular diseases.

[52]  J. Ambrose,et al.  Pathophysiology of coronary artery disease leading to acute coronary syndromes , 2015, F1000prime reports.

[53]  Gretchen J. Mahler,et al.  Effects of shear stress pattern and magnitude on mesenchymal transformation and invasion of aortic valve endothelial cells , 2014, Biotechnology and bioengineering.

[54]  Y. Bossé,et al.  A roadmap to investigate the genetic basis of bicuspid aortic valve and its complications: insights from the International BAVCon (Bicuspid Aortic Valve Consortium). , 2014, Journal of the American College of Cardiology.

[55]  K. Harjai,et al.  Aortic stenosis and coronary artery disease: what do we know? What don't we know? A comprehensive review of the literature with proposed treatment algorithms. , 2014, European heart journal.

[56]  F. Hu,et al.  Fruit and vegetable consumption and mortality from all causes, cardiovascular disease, and cancer: systematic review and dose-response meta-analysis of prospective cohort studies , 2014, BMJ : British Medical Journal.

[57]  T. Brown,et al.  Effect of sustaining lifestyle modifications (nonsmoking, weight reduction, physical activity, and mediterranean diet) after healing of myocardial infarction, percutaneous intervention, or coronary bypass (from the REasons for Geographic and Racial Differences in Stroke Study). , 2014, The American journal of cardiology.

[58]  Thoralf M Sundt,et al.  2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Journal of the American College of Cardiology.

[59]  S. Moebus,et al.  Beyond Framingham risk factors and coronary calcification: does aortic valve calcification improve risk prediction? The Heinz Nixdorf Recall Study , 2014, Heart.

[60]  L. Shaw,et al.  ACCF/AHA/ASE/ASNC/HFSA/HRS/SCAI/SCCT/SCMR/STS 2013 multimodality appropriate use criteria for the detection and risk assessment of stable ischemic heart disease: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Heart Association, American Societ , 2014, Journal of the American College of Cardiology.

[61]  G. Lucas,et al.  Pathogenesis of coronary artery disease: focus on genetic risk factors and identification of genetic variants , 2014, The application of clinical genetics.

[62]  B. Nordestgaard,et al.  Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population. , 2013, Journal of the American College of Cardiology.

[63]  M. Dweck,et al.  Calcific aortic stenosis: a disease of the valve and the myocardium. , 2012, Journal of the American College of Cardiology.

[64]  Paul Burton,et al.  Rivaroxaban in patients with a recent acute coronary syndrome. , 2012, The New England journal of medicine.

[65]  M. Olszowska.  Pathogenesis and pathophysiology of aortic valve stenosis in adults. , 2011, Polskie Archiwum Medycyny Wewnetrznej.

[66]  R. Weiss,et al.  Calcific Aortic Valve Stenosis: Methods, Models, and Mechanisms , 2011, Circulation research.

[67]  R. Collins,et al.  Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010, The Lancet.

[68]  Rosanna Abbate,et al.  Accruing evidence on benefits of adherence to the Mediterranean diet on health: an updated systematic review and meta-analysis. , 2010, The American journal of clinical nutrition.

[69]  S. Yusuf,et al.  Association of Diet, Exercise, and Smoking Modification With Risk of Early Cardiovascular Events After Acute Coronary Syndromes , 2010, Circulation.

[70]  K. Teo,et al.  Effect of Lipid Lowering With Rosuvastatin on Progression of Aortic Stenosis: Results of the Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin (ASTRONOMER) Trial , 2010, Circulation.

[71]  R. Collins,et al.  Genetic variants associated with Lp(a) lipoprotein level and coronary disease. , 2009, The New England journal of medicine.

[72]  T. Brady,et al.  Association of aortic valve calcification to the presence, extent, and composition of coronary artery plaque burden: from the Rule Out Myocardial Infarction using Computer Assisted Tomography (ROMICAT) trial. , 2009, American heart journal.

[73]  Stephen Kaptoge,et al.  Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. , 2009, JAMA.

[74]  R. Collins,et al.  Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials , 2009, The Lancet.

[75]  C. Lawson,et al.  ICAM-1 signaling in endothelial cells , 2009, Pharmacological reports : PR.

[76]  David R. Williams,et al.  Mental disorders among persons with heart disease - results from World Mental Health surveys. , 2008, General hospital psychiatry.

[77]  L. Tavazzi,et al.  Global secondary prevention strategies to limit event recurrence after myocardial infarction: results of the GOSPEL study, a multicenter, randomized controlled trial from the Italian Cardiac Rehabilitation Network. , 2008, Archives of internal medicine.

[78]  J. Chambers,et al.  Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. , 2008, The New England journal of medicine.

[79]  M. Enriquez-Sarano,et al.  Aortic Valve Calcification: Determinants and Progression in the Population , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[80]  K. O’Brien.  Pathogenesis of calcific aortic valve disease: a disease process comes of age (and a good deal more). , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[81]  C. Otto,et al.  Valvular aortic stenosis: disease severity and timing of intervention. , 2006, Journal of the American College of Cardiology.

[82]  R. Cury,et al.  Coronary CT angiography. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[83]  C. Leclercq,et al.  Valve replacement in patients with critical aortic stenosis and depressed left ventricular function: predictors of operative risk, left ventricular function recovery, and long term outcome , 2005, Heart.

[84]  P. Libby,et al.  Pathophysiology of Coronary Artery Disease , 2005, Circulation.

[85]  R. Prescott,et al.  A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. , 2005, The New England journal of medicine.

[86]  R. Bonow,et al.  Task Force 3: valvular heart disease. , 2005, Journal of the American College of Cardiology.

[87]  C. Otto,et al.  The bicuspid aortic valve: adverse outcomes from infancy to old age. , 2005, Circulation.

[88]  C. Otto,et al.  Hemodynamic Effects of the Angiotensin-Converting Enzyme Inhibitor, Ramipril, in Patients with Mild to Moderate Aortic Stenosis and Preserved Left Ventricular Function , 2004, Journal of Investigative Medicine.

[89]  J. Critchley,et al.  Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review. , 2003, JAMA.

[90]  Y. Adler,et al.  Nonobstructive aortic valve calcification: a window to significant coronary artery disease. , 2002, Atherosclerosis.

[91]  S. Achenbach,et al.  Progression of Aortic Valve Calcification: Association with Coronary Progression of Aortic Valve Calcification Association with Coronary Atherosclerosis and Cardiovascular Risk Factors , 2022 .

[92]  Salim Yusuf,et al.  Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients , 2000, The Lancet.

[93]  C. Otto,et al.  Physical examination in valvular aortic stenosis: correlation with stenosis severity and prediction of clinical outcome. , 1999, American heart journal.

[94]  E. Etchells,et al.  A bedside clinical prediction rule for detecting moderate or severe aortic stenosis , 1998, Journal of General Internal Medicine.

[95]  Catherine M. Otto,et al.  Clinical Factors Associated With Calcific Aortic Valve Disease , 1997 .

[96]  David Schultz,et al.  A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) , 1996, The Lancet.

[97]  J. Cohn,et al.  The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. , 1996, The New England journal of medicine.

[98]  C. Otto,et al.  Apolipoproteins B, (a), and E accumulate in the morphologically early lesion of 'degenerative' valvular aortic stenosis. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[99]  M. Vandenburg,et al.  A large scale comparative study in general practice with nitroglycerin spray and tablet formulations in elderly patients with angina pectoris , 1992, European Journal of Clinical Pharmacology.

[100]  Salim Yusuf,et al.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.

[101]  M. Thubrikar,et al.  Intramural stress as a causative factor in atherosclerotic lesions of the aortic valve. , 1985, Atherosclerosis.

[102]  M. Cheitlin,et al.  Congenital bicuspid aortic valve after age 20. , 1977, The American journal of cardiology.

[103]  E. Romagnoli,et al.  Management of concomitant coronary artery disease and aortic valve stenosis in the era of transcatheter aortic valve treatment , 2022, Mini-invasive Surgery.

[104]  OUP accepted manuscript , 2021, European Heart Journal.

[105]  OUP accepted manuscript , 2021, European Heart Journal.

[106]  W. März,et al.  Utilization of lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients at high and very-high cardiovascular risk: Real-world evidence from Germany. , 2018, Atherosclerosis.

[107]  J. De Sutter,et al.  2016 European Guidelines on cardiovascular disease prevention in clinical practice , 2012, European journal of preventive cardiology.

[108]  R. Califf,et al.  Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. , 2015, The New England journal of medicine.

[109]  S. Prasad,et al.  Calcific Aortic Valve Disease: Molecular Mechanisms and Therapeutic Approaches. , 2015, European cardiology.

[110]  M. Budoff,et al.  Relationship of aortic valve calcification with coronary artery calcium severity: the Multi-Ethnic Study of Atherosclerosis (MESA). , 2010, Journal of cardiovascular computed tomography.

[111]  S. Hagl,et al.  Receptor activator of nuclear factor κB ligand and osteoprotegerin regulate aortic valve calcification , 2004 .

[112]  F. Sebening,et al.  [Coronary artery disease]. , 1980, Verhandlungen der Deutschen Gesellschaft fur Herz- und Kreislaufforschung.

[113]  M. Mirowski,et al.  Mitral Stenosis , 1953 .

[114]  D. Warkentin.  Risk factors in coronary artery disease. , 1968, Journal of the Iowa Medical Society.